NTHI - NASDAQ
Neonc Technologies Holdings, Inc.
$4.35
-4.2%Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
At a Glance
Live SnapshotNeonc Technologies Holdings, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Neonc Technologies Holdings, Inc. Income Statement
NTHI • NASDAQ
| Neonc Technologies Holdings, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
REVENUE | |||||
40K | 83K | 70.5K | 20K | 0.0 | |
GROSS PROFIT | |||||
40K | 83K | 70.5K | 20K | 0.0 | |
OPERATING INCOME | |||||
(58.2M) | (7.2M) | (12.3M) | (2.9M) | (3.3M) | |
(42.9M) | (3.6M) | (3.4M) | (1.7M) | (2.6M) | |
(3.6M) | (3M) | (1.5M) | (1.2M) | (674.6K) | |
-58.2M | -7.1M | -12.2M | -2.8M | -3.3M | |
PRE-TAX INCOME | |||||
(2.5M) | (2.7M) | (2.7M) | (200.2K) | (112.9K) | |
-2.2M | -2.7M | -2.7M | -200.2K | -112.9K | |
(11.7M) | (541.3K) | (7.3M) | (0.0) | (0.0) | |
-4M | -4.8M | -2.7M | -209.2K | -103.9K | |
-62.1M | -11.9M | -14.9M | -3M | -3.4M | |
NET INCOME | |||||
-62.1M | -11.9M | -14.9M | -3M | -3.4M |
SEC Filings
NTHI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | May 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 24, 2026 | April 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 10, 2026 | April 10, 2026 | 2026 | |
S-3 S-3 N/A | April 10, 2026 | April 10, 2026 | ||
8-K 8-K 2026 N/A | April 03, 2026 | April 01, 2026 | 2026 | |
S-3 S-3 N/A | April 02, 2026 | April 02, 2026 | ||
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 |
Related Guides
Continue your NTHI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.